Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023

Nuvectis Pharma, Inc.

2023-Q2 EPS reported -$0.65

Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.
Net loss $5.7M vs $3.6M in Q2 2022; R&D expense $4.3M vs $2.5M.
NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; data expected Q1 2024.
NXP900 IND cleared by FDA; Phase 1a dose escalation study set to begin in Q3 2023.
Potential NXP800 expansion into cholangiocarcinoma supported by preclinical data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.

Period: the second quarter ended June 30, 2023
Net income: $5.7 million
Result: reported results

Exact text from the filing

Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.

Period: the second quarter ended June 30, 2023
Net income: $5.7 million
Result: reported results

Exact text from the filing

The Company's net loss was $5.7 million for the three months ended June 30, 2023, compared to $3.6 million for the three months ended June 30, 2022, an increase of $2.1 million.

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.